The global lung cancer diagnostics market size is estimated at USD 5.02 billion in 2024, grew to USD 5.35 billion in 2025 and is predicted to surpass around USD 9.45 billion by 2034, expanding at a CAGR of 6.53% between 2024 and 2034. The North America lung cancer diagnostics market size accounted for USD 2.38 billion in 2024 and is anticipated to grow at a fastest CAGR of 6.54% during the forecast year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Lung Cancer Diagnostics Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Lung Cancer Diagnostics Market, by Type, 2024-2034
8.1.1 Non-small cell lung cancer
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. Small cell lung cancer
8.1.2.1. Market Revenue and Forecast (2021-2034)
9.1. Lung Cancer Diagnostics Market, by Test, 2024-2034
9.1.1. CA test
9.1.1.1. Market Revenue and Forecast (2021-2034)
9.1.2. HER2 test
9.1.2.1. Market Revenue and Forecast (2021-2034)
9.1.3. ALK test
9.1.3.1. Market Revenue and Forecast (2021-2034)
9.1.4. Angiogenesis Inhibitors
9.1.4.1. Market Revenue and Forecast (2021-2034)
9.1.5. EGFR Mutation test
9.1.5.1. Market Revenue and Forecast (2021-2034)
9.1.6. KRAS Mutation test
9.1.65.1. Market Revenue and Forecast (2021-2034)
10.1. Lung Cancer Diagnostics Market, by End Use, 2024-2034
10.1.1. Hospitals and clinics
10.1.1.1. Market Revenue and Forecast (2021-2034)
10.1.2. Diagnostic Laboratories
10.1.2.1. Market Revenue and Forecast (2021-2034)
10.1.3. Others
10.1.3.1. Market Revenue and Forecast (2021-2034)
11.1. North America
11.1.1. Market Revenue and Forecast, by Type (2021-2034)
11.1.2. Market Revenue and Forecast, by Test (2021-2034)
11.1.3. Market Revenue and Forecast, by End Use (2021-2034)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Type (2021-2034)
11.1.4.2. Market Revenue and Forecast, by Test (2021-2034)
11.1.4.3. Market Revenue and Forecast, by End Use (2021-2034)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Type (2021-2034)
11.1.5.2. Market Revenue and Forecast, by Test (2021-2034)
11.1.5.3. Market Revenue and Forecast, by End Use (2021-2034)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Type (2021-2034)
11.2.2. Market Revenue and Forecast, by Test (2021-2034)
11.2.3. Market Revenue and Forecast, by End Use (2021-2034)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Type (2021-2034)
11.2.4.2. Market Revenue and Forecast, by Test (2021-2034)
11.2.4.3. Market Revenue and Forecast, by End Use (2021-2034)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Type (2021-2034)
11.2.5.2. Market Revenue and Forecast, by Test (2021-2034)
11.2.5.3. Market Revenue and Forecast, by End Use (2021-2034)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Type (2021-2034)
11.2.6.2. Market Revenue and Forecast, by Test (2021-2034)
11.2.6.3. Market Revenue and Forecast, by End Use (2021-2034)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Type (2021-2034)
11.2.7.2. Market Revenue and Forecast, by Test (2021-2034)
11.2.7.3. Market Revenue and Forecast, by End Use (2021-2034)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Type (2021-2034)
11.3.2. Market Revenue and Forecast, by Test (2021-2034)
11.3.3. Market Revenue and Forecast, by End Use (2021-2034)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Type (2021-2034)
11.3.4.2. Market Revenue and Forecast, by Test (2021-2034)
11.3.4.3. Market Revenue and Forecast, by End Use (2021-2034)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Type (2021-2034)
11.3.5.2. Market Revenue and Forecast, by Test (2021-2034)
11.3.5.3. Market Revenue and Forecast, by End Use (2021-2034)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Type (2021-2034)
11.3.6.2. Market Revenue and Forecast, by Test (2021-2034)
11.3.6.3. Market Revenue and Forecast, by End Use (2021-2034)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Type (2021-2034)
11.3.7.2. Market Revenue and Forecast, by Test (2021-2034)
11.3.7.3. Market Revenue and Forecast, by End Use (2021-2034)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Type (2021-2034)
11.4.2. Market Revenue and Forecast, by Test (2021-2034)
11.4.3. Market Revenue and Forecast, by End Use (2021-2034)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Type (2021-2034)
11.4.4.2. Market Revenue and Forecast, by Test (2021-2034)
11.4.4.3. Market Revenue and Forecast, by End Use (2021-2034)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Type (2021-2034)
11.4.5.2. Market Revenue and Forecast, by Test (2021-2034)
11.4.5.3. Market Revenue and Forecast, by End Use (2021-2034)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Type (2021-2034)
11.4.6.2. Market Revenue and Forecast, by Test (2021-2034)
11.4.6.3. Market Revenue and Forecast, by End Use (2021-2034)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Type (2021-2034)
11.4.7.2. Market Revenue and Forecast, by Test (2021-2034)
11.4.7.3. Market Revenue and Forecast, by End Use (2021-2034)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Type (2021-2034)
11.5.2. Market Revenue and Forecast, by Test (2021-2034)
11.5.3. Market Revenue and Forecast, by End Use (2021-2034)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Type (2021-2034)
11.5.4.2. Market Revenue and Forecast, by Test (2021-2034)
11.5.4.3. Market Revenue and Forecast, by End Use (2021-2034)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Type (2021-2034)
11.5.5.2. Market Revenue and Forecast, by Test (2021-2034)
11.5.5.3. Market Revenue and Forecast, by End Use (2021-2034)
12.1. F. Hoffmann-La Roche Ltd
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Thermo Fisher Scientific
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Illumina Inc
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Agilent Technologies
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Qiagen
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Abbott
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Bio-Rad
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Neogenomics Laboratories
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. bioMérieux
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Myriad Genetics, Inc
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample